Cite
Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)
MLA
Morschhauser, Franck, et al. “Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL).” Blood, vol. 142, no. 1, Number 1 Supplement 1, Nov. 2023, p. 605. EBSCOhost, https://doi.org/10.1182/blood-2023-174432.
APA
Morschhauser, F., Patel, K., Bobillo, S., Cordoba, R., Eyre, T. A., Bishton, M., Houot, R., Zhang, H.-L., Zou, L., Osborne, W., Gálvez-Carvajal, L., Thieblemont, C., Yee, D., Knapp, A., Purev, E., Li, H., Chen, V., Banta, K. L., Sit, J., & Bachy, E. (2023). Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL). Blood, 142(1, Number 1 Supplement 1), 605. https://doi.org/10.1182/blood-2023-174432
Chicago
Morschhauser, Franck, Krish Patel, Sabela Bobillo, Raul Cordoba, Toby A. Eyre, Mark Bishton, Roch Houot, et al. 2023. “Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL).” Blood 142 (1, Number 1 Supplement 1): 605. doi:10.1182/blood-2023-174432.